Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMP nasal spray for seasonal allergic rhinitis
ACTRN12607000494437Phase 2Not yet recruiting
- Sponsor
- Anzamune
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing CMP nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Change from baseline in the 4 symptom nasal score for the entire double-blind treatment period. Planned start Oct 2007; status: not yet recruiting.
02
Drugs
cytidine monophosphate
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on ACTRN12607000494437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000494437.